US2020248150A1PendingUtilityA1

Virus filtration of liquid factor VII compositions

Assignee: NOVO NORDISK HEALTHCARE AGPriority: Dec 1, 2003Filed: Apr 20, 2020Published: Aug 6, 2020
Est. expiryDec 1, 2023(expired)· nominal 20-yr term from priority
C07K 1/34C12N 7/00C12N 9/6437A61P 7/02C12N 2740/13063C07K 14/745C12Y 304/21021A61P 7/04
63
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention relates to a novel method for improving the viral safety of liquid Factor VII compositions, in particular those comprising active Factor VII polypeptides (a Factor VIIa polypeptide).

Claims

exact text as granted — not AI-modified
1 . A method for removing viruses from a liquid composition of recombinant Factor VII comprising one or more Factor VII polypeptides having a concentration in the range of 0.01 to 5 mg/mL, the method comprising subjecting the liquid composition to nanofiltration using a nanofilter having a pore size of 80 nm or less, wherein 50-100% of the Factor VII polypeptides in the composition subjected to the nanofilter are in an activated form (FVIIa) prior to nanofiltration. 
     
     
         2 . The method according to  claim 1 , wherein the liquid composition has a pH of in the range of 7.0-9.5. 
     
     
         3 . The method according to  claim 2 , wherein the pH is in the range of 8.3-8.7. 
     
     
         4 . The method according to  claim 1 , wherein the pore size of the nanofilter is 50 nm or less. 
     
     
         5 . The method according to  claim 1 , wherein the membrane of the nanofilter is manufactured from one or more materials selected from the group consisting of: cuprammonium regenerated cellulose, hydrophilic polyvinylidene fluoride (PVDF), composite PVDF, surface modified PVDF, and polyether sulfone. 
     
     
         6 . The method according to  claim 1 , wherein the pore size of the nanofilter is in the range of 10-30 nm. 
     
     
         7 . The method according to  claim 1 , wherein the liquid Factor VII composition is obtained from a cell culture supernatant. 
     
     
         8 . The method according to  claim 1 , wherein the liquid composition is serum-free. 
     
     
         9 . The method according to  claim 1 , wherein the Factor VII polypeptide(s) is/are produced by cell culture in the presence of bovine or foetal calf serum. 
     
     
         10 . The method according to  claim 1 , wherein the Factor VII polypeptide(s) is/are produced by cell culture in Chinese Hamster Ovary (CHO) cells in a medium free from any components of animal origin. 
     
     
         11 . The method according to  claim 1 , wherein the concentration of the Factor VII polypeptide(s) in the liquid composition is in the range of 0.05-2.0 mg/mL. 
     
     
         12 . A method for removing viruses from a liquid composition of recombinant Factor VII comprising one or more Factor VII polypeptides having a concentration in the range of 0.01 to 5 mg/mL, wherein 50-100% of the Factor VII polypeptides in the composition are in an activated form (FVIIa) prior to nanofiltration, the method comprising the steps of (i) combining the composition with a detergent, and (ii) subjecting the solution to nanofiltration using a nanofilter having a pore size of 80 nm or less. 
     
     
         13 . The method of  claim 1 , wherein 70-100% of the Factor VII polypeptides in the composition subjected to the nanofilter are the activated form of Factor VII. 
     
     
         14 . The method of  claim 1 , wherein 80-100% of the Factor VII polypeptides in the composition subjected to the nanofilter are the activated form of Factor VII. 
     
     
         15 . A method for removing viruses from a liquid composition of recombinant Factor VII comprising one or more Factor VII polypeptides having a concentration in the range of 0.01 to 5 mg/mL, the method comprising subjecting the liquid composition to nanofiltration using a nanofilter having a pore size of 50 nm or less, wherein 50-100% of the Factor VII polypeptides in the composition subjected to the nanofilter are in an activated form (FVIIa) prior to nanofiltration.

Join the waitlist — get patent alerts

Track US2020248150A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.